Boss Translational Medicine Ltd is categorized under Commercial Medical Research in Buffalo, NY and active since 2013.
Boss Translational Medicine Ltd was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Julian Ambrus at the company’s single location by writing to 541 West Ferry St, Buffalo, New York NY 14222 or by phoning (716) 882-2051. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Boss Translational Medicine Ltd |
| Contact Person: | Julian Ambrus |
| Address: | 541 West Ferry St, Buffalo, New York 14222 |
| Phone Number: | (716) 882-2051 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Boss Translational Medicine Ltd was started in 2013 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Julian Ambrus for inquiries that concern Boss Translational Medicine Ltd by calling the company number (716) 882-2051, as your correspondence is most welcome. Additionally, the physical location of the single location of Boss Translational Medicine Ltd can be found at the coordinates 42.91536,-78.880769 as well as the street address 541 West Ferry St in Buffalo, New York 14222.
For its online presence, you may visit Boss Translational Medicine Ltd’s website at and engage with its social media outlets through on Twitter and on Facebook.